論文

国際誌
2022年3月17日

Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture.

Journal of radiation research
  • Nobuteru Kubo
  • Daijiro Kobayashi
  • Mototaro Iwanaga
  • Masana Matsuura
  • Keiko Higuchi
  • Jun Eishima
  • Hiroyuki Muramatsu
  • Naoko Okano
  • Mariko Shioya
  • Masahiro Onishi
  • Tetsuya Aoki
  • Takahiro Oike
  • Tatsuya Ohno
  • 全て表示

63
2
開始ページ
264
終了ページ
271
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/jrr/rrab116

The promising results of the PACIFIC study led to the approval of consolidation durvalumab for coverage by the National Health Insurance (NHI) in 2018 for patients with locally-advanced unresectable non-small cell lung carcinoma (NSCLC) treated with definitive concurrent chemoradiotherapy (CCRT). However, the effect of NHI coverage on the patterns of care for this population remains unclear. Here, we conducted a questionnaire-based survey to determine the patterns of care for patients with stage II-III NSCLC treated with definitive radiotherapy in 2017 (pre-durvalumab era) or in 2019 (post-durvalumab era). Data were obtained from 11 radiotherapy facilities in Gunma prefecture, which has a population of 1.94 million. We identified 80 and 83 patients with stage II-III NSCLC who received definitive radiotherapy in Gunma in 2017 and 2019, respectively. At a given facility, CCRT was the treatment of choice in a significantly greater proportion of patients in 2019 than in 2017 (66% ± 20% vs 51% ± 29%, P = 0.041). Intensity-modulated radiotherapy (IMRT) was more frequent in 2019 than in 2017 (24% vs 1.2%). Carboplatin plus paclitaxel was used for CCRT at higher rate in 2019 than in 2017 (73% vs 44%). Consolidation durvalumab was performed in 73% (40/55) of CCRT-treated patients in 2019, and the treatment was performed for the planned 12 months in 45% (18/40) of patients. These data indicate that NHI coverage of durvalumab might be a possible reason for choosing CCRT in patients with stage II-III NSCLC in the real-world setting.

リンク情報
DOI
https://doi.org/10.1093/jrr/rrab116
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34970980
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944323
ID情報
  • DOI : 10.1093/jrr/rrab116
  • PubMed ID : 34970980
  • PubMed Central 記事ID : PMC8944323

エクスポート
BibTeX RIS